News

The portfolio includes leading brands built by strong levels of professional recommendations which have demonstrated excellent growth potential. The brands Lipo-Flavonoid®, Certain Dri®, Cystex®, Albolene, Absorbine Jr.®, and

If successful, the company could then move forward with medical research investigating whether or not the product is efficacious in areas like cancer, post-traumatic stress disorder, concussions, epilepsy,

The study is the first time a targeted nanotherapeutic approach to microRNA replacement is being tested in patients with MPM. EnGeneIC’s EDV nanocells will be packaged with miR-16

A new recombinant FVIII, Nuwiq is produced in a human cell line cultured without additives of human or animal origin or any exposure to human blood or plasma,

Trulicity comes in a single-dose pen and does not require the patient to mix, measure, or handle the needle and it is not recommended as first-line therapy for

With the exclusive license, Pharco will now be able to expand its licensed territory to one or more additional countries in the Middle East and North Africa (MENA)

Evolocumab inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that reduces the liver’s ability to remove low-density lipoprotein cholesterol (LDL-C) or bad cholesterol from the blood. The

DCV is a fixed-dose combination of daclatasvir 30mg with asunaprevir 200mg (ASV) and beclabuvir 75mg (BCV). Primary endpoint for the two trials was the percentage of patients who

Alios, which is focused on developing therapies for viral diseases, will now be part of the infectious diseases therapeutic area of the Janssen Pharmaceutical Companies of J&J. The